Johnson & Johnson's Impella pVAD Registration Halted in China Amid Safety Concerns and Rising Domestic Competition

On June 22, 2026, the Center for Medical Device Evaluation of the National Medical Products Administration (NMPA) issued a public notice terminating the registration review. The Impella “Percutaneous Left Ventricular Assist Pump System” (Application No.: JQZ2500182), distributed by Johnson & Johnson Medical (Shanghai) Ltd., had its registration officially terminated. This means that the launch timeline in China for Impella, a global benchmark product in the percutaneous ventricular assist device (pVAD) category, has been forcibly delayed.

However, “termination of registration review” does not mean that the product is permanently barred from market entry. According to China’s medical device evaluation regulations, termination of the registration process typically arises from two scenarios: voluntary withdrawal of the submission materials by the applicant, or failure to submit supplementary materials within the statutory one-year timeframe. Therefore, Impella may still reapply for registration in the future, but its current commercialization timeline has been “disrupted.”

| What is pVAD? What problem does Impella address?

pVAD (Percutaneous Ventricular Assist Device) is a class of short-term mechanical circulatory support devices that are inserted into the heart via peripheral vessels through minimally invasive interventional techniques. Its core function is to provide patients with stable hemodynamic support during the most critical window period of cardiac vulnerability.

Impella is the global benchmark for this class of devices, known as the “world’s smallest heart pump.” Its core mechanism involves percutaneous insertion via the femoral artery into the left ventricle, where it actively pumps blood from the left ventricle into the aorta, providing short-term circulatory support. Taking the Impella CP with SmartAssist as an example, it delivers a maximum peak flow rate of up to 4.3 L/min—thereby securing a stable hemodynamic window for patients during the most critical and vulnerable phases of cardiac dysfunction.

It differs from traditional assist devices such as IABP and ECMO. IABP is easy to insert and has a lower complication rate, but it can only increase cardiac output by approximately 10%–20%, offering limited support capability. ECMO can significantly increase cardiac output, but its operation is complex and it may increase left ventricular afterload, making it more suitable for critically ill patients with conditions such as respiratory failure or cardiac arrest. The core value of Impella lies in its ability to more directly unload the left ventricle, improve coronary perfusion, and provide active circulatory support to high-risk patients through minimally invasive interventional techniques.

Public data projections indicate that the volume of high-risk percutaneous coronary intervention (PCI) procedures in China is expected to reach 772,000 by 2033. Approximately 308,000 patients annually suffer from acute myocardial infarction complicated by cardiogenic shock, a population with a persistently high mortality rate. Furthermore, there is a demand for short-term mechanical circulatory support in scenarios such as acute decompensated heart failure, low cardiac output syndrome following cardiac surgery, and support during off-pump coronary artery bypass grafting. This signifies that percutaneous ventricular assist devices (pVADs) are not a niche tool in China, but rather a critical therapeutic equipment category for high-risk PCI, cardiogenic shock, the acute phase of heart failure, and the perioperative period of cardiac surgery.

Meanwhile, according to Frost & Sullivan’s forecasts, the market size for short- to medium-term ventricular assist devices in China will exceed RMB 11 billion by 2033, with a compound annual growth rate (CAGR) of 16.7%. Among these, percutaneous left ventricular assist pumps represent one of the most high-growth segments, precisely because they address multiple high-value clinical scenarios.

| Impella, the Imported Benchmark, Still Faces Obstacles

Impella is the only percutaneous ventricular assist device (pVAD) approved by the U.S. FDA worldwide, and it has long dominated the global pVAD market. In 2022, Johnson & Johnson acquired Impella’s parent company, Abiomed, for $16.6 billion. Since then, Impella has continued to drive growth—according to Johnson & Johnson’s annual report and related media coverage, Impella generated approximately $1.75 billion in revenue (about RMB 11.9 billion) in fiscal year 2025.

Despite the termination of its registration, Impella is not entirely “absent” from the Chinese market.

In March 2026, the first batch of four Impella devices entered Beijing through the “green channel” for temporary import of clinically urgent drugs and medical devices, and were put into use at Fuwai Hospital and Anzhen Hospital for clinical emergency treatment of critically ill patients. This also marks the first clinically urgent medical device approved via the national green channel in the Beijing region.

Wang Xianqiang, Director of the Adult Cardiac Surgery Center at Fuwai Hospital, further stated, “There is currently substantial evidence from evidence-based medicine and clinical practice demonstrating that Impella is a relatively safe and effective short-term mechanical circulatory support device, offering new therapeutic options for patients with critical heart failure.”

However, over the past year, Impella has undergone multiple Class I recalls under the FDA system: In March 2024, the FDA issued its highest-level recall due to the risk of the pump catheter perforating the left ventricular wall, involving reports of 49 deaths and 129 serious injuries; in May 2026, the FDA issued another early alert pointing out software errors in the automatic controller that could cause the pump to stop for 35 seconds, with one death and two serious injuries reported.

Thus, while these events do not negate its clinical value, they demonstrate that the Chinese market imposes higher requirements for safety data, risk control measures, and localized evidence regarding pVADs as high-risk life support devices.

| Domestic pVADs Achieve Collective Breakthrough

As Impella faces registration hurdles, domestically produced percutaneous ventricular assist devices (pVADs) are accelerating their market entry. In December 2025, Core Medical’s CorVad system received approval, becoming the first approved interventional artificial heart product in China and marking a breakthrough for domestic manufacturers. In June 2026, Fengkaili’s SynFlow® 3.0 system swiftly followed suit in obtaining regulatory clearance. Additionally, companies such as HeartGear Medical, XinHengRui, and Huanqing Medical are advancing their R&D and clinical validation at various stages. According to industry statistics, more than 10 companies have invested in pVAD development, with 2026 regarded by the industry as the “year of collective approvals” for domestic pVADs.

However, obtaining regulatory approval is merely an entry ticket. The true competition in this field will not hinge solely on “who gains approval first” or “the higher the pump flow rate, the better,” but will instead center on comprehensive capabilities, including flow support, access size, hemolysis control, duration of support, weaning management, bedside management, physician training, and clinical evidence.

The long-term advantages of Impella lie precisely in its comprehensive body of clinical evidence, training system, and application pathways that have been accumulated over time. For domestic manufacturers, the key determinants of ultimate success will be their ability to gain access to top-tier hospitals, accumulate real-world data, establish robust training systems, and achieve effective cost control.